AstraZeneca Amolyt Pharma takeover ‘sufficiently modest' - analysts

AstraZeneca PLC (LSE:AZN)’s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts. According to the bank, the acquisition “is sufficiently modest to pass under the radar without any visible impact on leverage or profit and losses”. Indeed, net debt and pre-tax earnings came in at US$22.5 billion and US$13.6 billion over the last full year respectively, Deutsche noted. Deutsche reiterated a ‘sell’ rating for AstraZeneca as a result, wit ...